Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development
Reference number: GID-TA11215
Expected publication date:
Please note that following conversations between NICE and the company this topic has been scheduled into the work programme.
The appraisal is now anticipated to begin will begin during early January 2025 when we will write to you about how you can get involved.